JamesBreitmeyerMDPhD

PubMed

• Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
  Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman, Minya Pu, Elizabeth Weihe, Emanuela M Ghia, Laura Z Rassenti, Alfredo Molino...> ;Breast Cancer Research. 2024 Mar 13
• 1 citations
  A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
  Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman, Minya Pu, Elizabeth Weihe, Emanuela M Ghia, Laura Z Rassenti, Alfredo Molino...> ;Breast Cancer Research. 2024 Feb 26
• 5 citations
  The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells.
  Dongli Liu, Gunnar F Kaufmann, James B Breitmeyer, Kristie-Ann Dickson, Deborah J Marsh, Caroline E Ford> ;Pharmaceutics. 2022 Apr 11
• 20 citations
  Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T ...
  Susan P. Foy, Stefanie Mandl, Tracy dela Cruz, Joseph Cote, Evan Gordon, Erica Trent, Alain Delcayre, James Bradley Breitmeyer, Alex Franzusoff, Ryan Rountree> ;Cancer Immunology, Immunotherapy. 2016 Mar 10
• 58 citations
  Intravenous acetaminophen for pain after major orthopedic surgery: an expanded analysis.
  Raymond S. Sinatra, Jonathan S. Jahr, Lowell Reynolds, Scott B. Groudine, JD Mike A. Royal Md, James B. Breitmeyer, Eugene R. Viscusi> ;Pain Practice. 2012 Jun 1
• 22 citations
  Safety and efficacy of intravenous acetaminophen in the elderly after major orthopedic surgery: subset data analysis from 3, randomized, placebo-controlled trials.
  Jonathan S. Jahr, James B. Breitmeyer, Christine Pan, Mike A. Royal, Robert Y. Ang> ;American Journal of Therapeutics. 2012 Mar 1
• A randomized study of the efficacy and safety of intravenous acetaminophen vs. intravenous placebo for the treatment of fever.
  Kett, D. H., Breitmeyer, J. B., Ang, R., Royal, M. A.> ;Clin Pharmacol Ther. 2011 Jul
• 26 citations
  A randomized study of the efficacy and safety of intravenous acetaminophen compared to oral acetaminophen for the treatment of fever.
  W. Frank Peacock, James B. Breitmeyer, Christine Pan, William B. Smith, Mike A. Royal> ;Academic Emergency Medicine. 2011 Apr 1
• 24 citations
  A review of the literature on the effects of acetaminophen on pregnancy outcome.
  Anthony R. Scialli, Robert Y. Ang, James B. Breitmeyer, Mike A. Royal> ;Reproductive Toxicology. 2010 Dec 1
• 18 citations
  Childhood asthma and use during pregnancy of acetaminophen. A critical review.
  Anthony R. Scialli, Robert Y. Ang, James B. Breitmeyer, Mike A. Royal> ;Reproductive Toxicology. 2010 Dec 1
• 94 citations
  A randomized, double-blind, placebo-controlled, multicenter, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdomin...
  Steven J. Wininger, Howard Miller, Harold S. Minkowitz, Mike A. Royal, Robert Y. Ang, James B. Breitmeyer, Neil Singla> ;Clinical Therapeutics. 2010 Dec 1
• 172 citations
  Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
  Julie A. Bowles, Siao-Yi Wang, Brian K. Link, Allan Barrett W, Gregory Beuerlein, Mary-Ann Campbell, David Matthew Marquis, Brian Ondek, James E. Wooldridge, Brian J. ...> ;Blood. 2005 Nov 16
• 13 citations
  A Phase I Study of Recombinant Interferon-β in Patients with Advanced Malignant Disease
  Farhad Ravandi, Zeev Estrov, Razelle Kurzrock, James B. Breitmeyer, Birgit J. Maschek, Moshe Talpaz> ;Clinical Cancer Research. 1999 Dec 1
• 220 citations
  Recombinant Human Growth Hormone in Patients with HIV-Associated Wasting: A Randomized, Placebo-Controlled Trial
  Morris Schambelan, Kathleen Mulligan, Carl Grunfeld, Eric S. Daar, Anthony LaMarca, Donald P. Kotler, Jack Wang, Samuel A. Bozzette, James B. Breitmeyer> ;Annals of Internal Medicine. 1996 Dec 1
• 11 citations
  Recombinant Human Interferon-β (rHuIFN-β) and Radiation Therapy for Inoperable Non-Small Cell Lung Cancer
  Roger W. Byhardt, Louis Vaickus, Patricia L. Witt, A Y Chang, Timothy L. McAuliffe, J. Frank Wilson, Colleen A. Lawton, James B. Breitmeyer, Mary Ellen Alger, Ernest C...> ;Journal of Interferon & Cytokine Research. 1996 Nov 1
• 2 citations
  Platelet transfusion and alternatives to transfusion in patients with malignancy
  Louis Vaickus, James B. Breitmeyer, Robert L. Schlossmann, Kenneth C. Anderson> ;Stem Cells. 1995 Jan 1
• 1 citations
  Immunotherapy of breast cancer.
  James B. Breitmeyer> ;Cancer Treatment and Research. 1992 Jan 1
• 10 citations
  Genetic reconstitution of the T cell receptor (TcR) α/β heterodimer restores the association of CD3 ζ2 with the TcR/CD3 complex
  Richard S. Blumberg, Jaime Sancho, Steven C. Ley, Francis V. McDermott, Kut-Nie Tan, James Breitmeyer, C Terhorst> ;European Journal of Immunology. 1991 Feb 1
• 5 citations
  Adjuvant chemotherapy of breast cancer.
  James B. Breitmeyer, I. Craig Henderson> ;The Surgical Clinics of North America. 1990 Oct 1
• 35 citations
  Comprehensive management of disseminated breast cancer.
  I. C. Henderson, Judy Garber, J. B. Breitmeyer, Daniel F. Hayes, Jay R. Harris> ;Cancer. 1990 Sep 15
• Assembly and function of the T cell antigen receptor. Requirement of either the lysine or arginine residues in the transmembrane region of the alpha chain.
  Blumberg, R. S., Alarcon, B., Sancho, J., McDermott, F. V., Lopez, P., Breitmeyer, J., Terhorst, C.> ;J Biol Chem. 1990 Aug 15
• 11 citations
  Adjuvant systemic therapy for patients with node-negative tumors.
  I. C. Henderson, Daniel F. Hayes, Leroy M. Parker, Susan Love, Judy Garber, Abram Recht, J. B. Breitmeyer, Jay R. Harris, George P. Canellos> ;Cancer. 1990 May 1
• 4 citations
  Analysis of T lymphocyte subsets in all stages of diabetes.
  Denise L. Faustman, George S. Eisenbarth, James B. Breitmeyer> ;Journal of Autoimmunity. 1990 Apr 1
• 46 citations
  FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation
  Nam H. Dang, David A. Hafler, Stuart F. Schlossman, James B. Breitmeyer> ;Cellular Immunology. 1990 Jan 1
• 56 citations
  Abnormal T-lymphocyte subsets in type I diabetes.
  Denise L. Faustman, George S. Eisenbarth, John Daley, James B. Breitmeyer> ;Diabetes. 1989 Nov 1
• Join now to see all

Journal Articles

• PROSTVAC, PSA-targeted immunotherapy: New evidence for mechanism of action  
  Mandl SJ, Rountree RB, Owen RB, dela Cruz T, Hwang O, Paranjpe G, Enstrom A, Franzusoff AJ, Goessl C, Breitmeyer JB, J Clin Oncol, 1/1/2014
• Antitumor efficacy of poxvirus-based active immunotherapy alone and in combination with subtherapeutic dosing with immune checkpoint inhibitors  
  Foy SP, Rountree RB, Cote J, Gordon E, Trent E, Franzusoff AJ, Breitmeyer JB, Mandl SJ, J Clin Oncol, 1/1/2014
• Intravenous Acetaminophen for Pain after Major Orthopedic Surgery: An Expanded Analysis  
  Sinatra RS, Jahr JS, Reynolds L, Groudine SB, Royal MA, Breitmeyer JB, Viscusi ER, Pain Practice, 1/1/2012
• A randomized study of the efficacy and safety of intravenous acetaminophen compared to oral acetaminophen for the treatment of fever  
  Peacock WF, Breitmeyer J, Pan C, Smith WB, Royal MA, Acad. Emerg. Med. Acad Emerg Med, 1/1/2011
• A randomized, double-blind, placebo-controlled, multi-center, repeat-dose study of two intravenous acetaminophen dosing regimens for the treatment of pain after abdomi...  
  Wininger SJ, Miller H, Minkowitz HS, Royal MA, Ang RY, Breitmeyer JB, Singla NK, Clin Ther, 1/1/2010
• Childhood asthma and use during pregnancy of acetaminophen: a critical review  
  Scialli AR, Ang R, Breitmeyer J, Royal MA, Reprod Toxicol, 1/1/2010
•  
  Tutuncu Z, Boyle D, Breitmeyer J, Kavanaugh A, ACR, 1/1/2006
• A Dose Escalation, Open-Label, Phase I/II Study of AME-527, A Novel Anti-TNF Monoclonal Antibody (mAb) in Subjects with Active Rheumatoid Arthritis  
  Tutuncu Z, Boyle D, Lee S, Hallinan J, Weber J, Vasserot A, Breitmeyer J, Kavanaugh A, ACR, 1/1/2005
• Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretrovira...  
  Moyle GJ, Daar ES, Gertner JM, Kotler DP, Melchior JC, O’Brien F, Svanberg E, J Acquir Immune Defic Syndr, 1/1/2004
• AME-133: A Next-Generation Anti-CD20 Engineered for Enhanced Killer Function  
  Breitmeyer, JB; Campbell, MA; Allan, B; Marquis, D; Ondek, B; Watkins, J, J Immunother, 1/1/2004
• Hypogonadism is uncommon in men with AIDS-associated wasting  
  Gertner JM, BreitmeyerJB, Kennedy SM, ICAC, 1/1/1998
• Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer  
  Byhardt RW, Vaickus L, Witt PL, Chang AY, McAuliffe T, Wilson JF, Lawton CA, BreitmeyerJ, Alger ME, Borden EC, J. Interferon & Cytokine Research, 1/1/1996
• Effect of continuous growth hormone therapy on lean body mass (LBM) and AIDS-defining events in HIV-associated wasting (HIV-W)  
  Daar ES, LaMarca A, Schambelan M, Grunfeld C, Mulligan K, BreitmeyerJ, 3rd Conf Retro and Opportun Infect, 1/1/1996
• Recombinant, mammalian cell-derived human growth hormone (r- hGH[m]) does not increase HIV replication in vitro or in treated patients  
  Daar ES, Polsky B, Mellors J, BreitmeyerJ, 3rd Conf Retro and Opportun Infect, 1/1/1996
• Immunomodulatory effects of mammalian cell-derived human recombinant growth hormone (r-hGH[m]) in patients with AIDS wasting  
  Denny TN, Landy H, BreitmeyerJB, 3rd Conf Retro and Opportun Infect, 1/1/1996
• A phase III study of recombinant human growth hormone (mammalian cell-derived) in patients with AIDS wasting  
  Berger DS, LaMarca A, Landy H, Kauffman RS, BreitmeyerJ, Int Conf AIDS, 1/1/1996
• Clinical relevance of DEXA-determined lean body mass in patients with AIDS wasting  
  Pierson R, Wang J, Landy H, BreitmeyerJ, Kotler D, Int Conf AIDS, 1/1/1996
• Recombinant human growth hormone in patients with HIV-associated wasting A randomized, placebo-controlled trial  
  Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozzette SA, BreitmeyerJB, Ann Intern Med, 1/1/1996
• Phase IA/IB evaluation of mammalian cell-derived glycosylated recombinant human interleukin 6 before and after cytotoxic chemotherapy  
  Ritch PS, Keever C, Schiller J, Rivkin S, Witt PL, Grossberg SE, Truitt RL, Burris H, Von Hoff DD, Vaickus L, Drechsler D, Borden EC, Galazka A, BreitmeyerJB, Abdul-Ah..., Ann NY Acad Sci, 1/1/1995
• Recombinant human growth hormone (rhGH) increases lean body mass (LBM) and improves functional performance in patients with HIV-associated wasting  
  Schambelan M, Mulligan K, Grunfeld C, Daar E, Lamarca A, BreitmeyerJ, Natl Conf Hum Retroviruses Relat Infect, 1/1/1995
• Phase I trial of recombinant beta-interferon (r-IFNbeta; R-FRONE) and radiation therapy (RT) for non-small cell lung cancer (NSCLC)  
  Byhardt RW, Vaickus L, Witt PL, Chang AY, McAuliffe T, Wilson JF, Lawton CA, BreitmeyerJ, Alger ME, Borden EC, Proc Annu Meet Am Soc Clin Oncol, 1/1/1994
• Growth hormone therapy of AIDS wasting  
  Schambelan M, LaMarca A, Mulligan K, Grunfeld C, Kennedy S, Int Conf AIDS, 1/1/1994
• Human recombinant interleukin-6 activated peripheral blood monocytes in vitro and in vivo  
  Witt PL, Keever C, Ritch PS, Truitt RL, Grossberg SE. BreitmeyerJB, Proc Annu Meet Am Assoc Cancer Res, 1/1/1994
• Genetic reconstitution of the T cell receptor alpha-beta heterodimer restores the association of CD3-zeta 2 with the T cell receptor/CD3 complex  
  Blumberg RS, Sancho J, Ley SC, McDermott FV, Tan K-N, BreitmeyerJ and Terhorst C, Eur J Immunology, 1/1/1991
• Analysis of T lymphocyte subsets in all stages of diabetes  
  Faustman D, Eisenbarth G, and BreitmeyerJ, Journal of Autoimmunity, 1/1/1990
• Join now to see all

Books/Book Chapters

• Immunotherapy of breast cancer 
  BreitmeyerJB1992
• Breast Diseases 
  Chapter: Immunological aspects of breast tumor biology 
  BreitmeyerJBEditors: Harris J, Hellman S, Henderson IC and Kinne D.J B Lippincott, Pholadelphia, PA1991
• Breast Diseases 
  Chapter: New forms of systemic therapy of metastatic breast cancer including immunotherapy 
  Breast DiseasesEditors: Harris J, Hellman S, Henderson IC and Kinne D.J B Lippincott, Philadelphia, PA1990
• Cellular Basis of Immune Modulation 
  Chapter: CD4 and CD8 molecules influence T cell receptor function: Evidence from monoclonal antibody binding studies 
  BreitmeyerJB, Anderson PA, Daley JF and Schlossman SFEditors: Kaplan JG, Green DR and Bleackley RC.A.R. Liss, Inc., New York, NY1989
• Leukocyte Typing III 
  Chapter: T-cell calcium mobilization by T11 (CD2) antibodies requires cell surface expression of the antigen receptor complex 
  Breitmeyer J, Daley J, Levine H and Schlossman SEditors: Oxford University Press.1987
• Washington University Manual of Medical Therapeutics 
  Chapter: Anemia and transfusion therapy 
  Page 284 - 298BreitmeyerJBEditors: Orland MJ and Saltman RJ.Little, Brown and Co., Boston, MA1986
• Join now to see all

Abstracts/Posters

• Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
  James B. Breitmeyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
  James B. Breitmeyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Anti-B4 blocked ricin immunotherapy for patients with B cell malignancies: Phase I trial of 7 day continuous infusion
  Nadler L, BreitmeyerJ, Grossbard M, Spector N, Rabinowe S, Coral F, Ritz J, Schlossman S, Blood, 1/1/1990

Lectures

• Anti-B4 blocked ricin immunotherapy for patients with B cell malignancies: Phase I trial of 7 day continuous infusion 
  1/4/1990
• Inhibition of breast cancer cell growth in vitro by a new monoclonal antibody, BC78 
  Las Vegas, NV - 1/5/1988